Can an antibiotic save your sight? new study tests minocycline for macular degeneration
NCT ID NCT02564978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the antibiotic minocycline, taken as a pill twice daily for at least 3 years, could safely slow the growth of geographic atrophy—an advanced form of age-related macular degeneration that causes blind spots. Thirty-seven adults aged 55 and older with geographic atrophy in at least one eye participated. The main goal was to see if the drug reduced the rate of vision loss compared to a pre-treatment observation period.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a VR maze reveal hidden vision loss in macular degeneration?
- Can a new eye injection save vision in wet AMD?
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness
- Could light therapy help save sight in dry macular degeneration?